Form 4/A for FTH Faeth Therapeutics, Inc.
Accepted 2022-04-21 00:00:00 ET · period of report 2021-02-18 · accession 0001567619-22-008798 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-04-21 | 2021-02-18 | FTH | Cambrian BioPharma Inc | 10% | P - Purchase | $19.75 | +752 | 4.69M | +0.0% | +$14.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-02-18 | P | A | 752 | $19.75 | 4,690,905 | D | — | — | (F1) This Form 4 is being amended to correct the number of shares purchased. The original Form 4 filed on February 19, 2021, overstated the number of shares purchased. (F2) These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares. |